155 related articles for article (PubMed ID: 11026693)
1. Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.
Frankel B; Longo SL; Canute GW
J Neurooncol; 2000 May; 48(1):21-6. PubMed ID: 11026693
[TBL] [Abstract][Full Text] [Related]
2. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer.
Song E; Chen J; Ouyang N; Su F; Wang M; Heemann U
Br J Cancer; 2001 Sep; 85(7):1047-54. PubMed ID: 11592778
[TBL] [Abstract][Full Text] [Related]
3. Fas/Fas ligand interactions are involved in ultraviolet-B-induced human lymphocyte apoptosis.
Caricchio R; Reap EA; Cohen PL
J Immunol; 1998 Jul; 161(1):241-51. PubMed ID: 9647230
[TBL] [Abstract][Full Text] [Related]
4. Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells.
Oyaizu N; Kayagaki N; Yagita H; Pahwa S; Ikawa Y
Biochem Biophys Res Commun; 1997 Sep; 238(2):670-5. PubMed ID: 9299572
[TBL] [Abstract][Full Text] [Related]
5. Soluble Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis.
Hashimoto H; Tanaka M; Suda T; Tomita T; Hayashida K; Takeuchi E; Kaneko M; Takano H; Nagata S; Ochi T
Arthritis Rheum; 1998 Apr; 41(4):657-62. PubMed ID: 9550474
[TBL] [Abstract][Full Text] [Related]
6. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.
Kim JW; Wieckowski E; Taylor DD; Reichert TE; Watkins S; Whiteside TL
Clin Cancer Res; 2005 Feb; 11(3):1010-20. PubMed ID: 15709166
[TBL] [Abstract][Full Text] [Related]
7. [The "Fas counterattack": a mechanism for immune evasion in human hilar cholangiocarcinomas].
Li Z; Zhang L; Zou S
Zhonghua Yi Xue Za Zhi; 2002 May; 82(9):606-9. PubMed ID: 12133481
[TBL] [Abstract][Full Text] [Related]
8. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
Bremer E; ten Cate B; Samplonius DF; de Leij LF; Helfrich W
Blood; 2006 Apr; 107(7):2863-70. PubMed ID: 16332967
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of Fas ligand by shedding.
Tanaka M; Itai T; Adachi M; Nagata S
Nat Med; 1998 Jan; 4(1):31-6. PubMed ID: 9427603
[TBL] [Abstract][Full Text] [Related]
10. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL
Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320
[TBL] [Abstract][Full Text] [Related]
11. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
12. Role of soluble Fas ligand in autoimmune diseases.
Li NL; Nie H; Yu QW; Zhang JY; Ma AL; Shen BH; Wang L; Bai J; Chen XH; Zhou T; Zhang DQ
World J Gastroenterol; 2004 Nov; 10(21):3151-6. PubMed ID: 15457562
[TBL] [Abstract][Full Text] [Related]
13. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
Suzuki N; Ichino M; Mihara S; Kaneko S; Sakane T
Arthritis Rheum; 1998 Feb; 41(2):344-53. PubMed ID: 9485093
[TBL] [Abstract][Full Text] [Related]
15. Epithelial ovarian cancer cells secrete functional Fas ligand.
Abrahams VM; Straszewski SL; Kamsteeg M; Hanczaruk B; Schwartz PE; Rutherford TJ; Mor G
Cancer Res; 2003 Sep; 63(17):5573-81. PubMed ID: 14500397
[TBL] [Abstract][Full Text] [Related]
16. Fas ligand in human serum.
Tanaka M; Suda T; Haze K; Nakamura N; Sato K; Kimura F; Motoyoshi K; Mizuki M; Tagawa S; Ohga S; Hatake K; Drummond AH; Nagata S
Nat Med; 1996 Mar; 2(3):317-22. PubMed ID: 8612231
[TBL] [Abstract][Full Text] [Related]
17. Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.
Zhang W; Ding EX; Wang Q; Zhu DQ; He J; Li YL; Wang YH
World J Gastroenterol; 2005 Jun; 11(23):3632-5. PubMed ID: 15962391
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of metalloproteinase cleavage enhances the cytotoxicity of Fas ligand.
Knox PG; Milner AE; Green NK; Eliopoulos AG; Young LS
J Immunol; 2003 Jan; 170(2):677-85. PubMed ID: 12517928
[TBL] [Abstract][Full Text] [Related]
19. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells.
Martínez-Lorenzo MJ; Alava MA; Gamen S; Kim KJ; Chuntharapai A; Piñeiro A; Naval J; Anel A
Eur J Immunol; 1998 Sep; 28(9):2714-25. PubMed ID: 9754559
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of nonspecific cytotoxic cell regulation of apoptosis: cytokine-like activity of Fas ligand.
Bishop GR; Taylor S; Jaso-Friedmann L; Evans DL
Fish Shellfish Immunol; 2002 Jul; 13(1):47-67. PubMed ID: 12201652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
